Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer presents aggressive behavior and resistance to current treatments.
• While BRAF V600E inhibitors show activity in non-small cell lung cancer (NSCLC), a significant portion of patients progress, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To investigate novel therapeutic strategies for BRAF-mutated NSCLC.
• To evaluate the efficacy of combining vemurafenib (a BRAF V600E inhibitor) with erlotinib or trametinib (a MEK inhibitor).

Main Methods:

• Assessed the synergistic effects of vemurafenib and erlotinib on p-ERK signaling in BRAF-V600E cells.
• Determined the impact of vemurafenib monotherapy on apoptosis, cell cycle arrest, and BIM expression in BRAF-V600 cells.
• Evaluated trametinib as a single agent in BRAF-mutated cells (V600E and non-V600E).
• Examined the combination of vemurafenib and trametinib for effects on apoptosis, BIM, and p-AKT signaling in BRAF non-V600 mutated cells.

Main Results:

• The combination of vemurafenib and erlotinib did not show synergy in inhibiting p-ERK signaling.
• Vemurafenib monotherapy induced significant apoptosis, G1 arrest, and BIM upregulation in BRAF-V600 cells.
• Trametinib demonstrated efficacy as a single agent across different BRAF mutation types.
• The combination of vemurafenib and trametinib resulted in a modest but significant increase in apoptosis and BIM upregulation compared to single agents.
• Trametinib alone upregulated p-AKT in BRAF non-V600 mutated cells, an effect nullified by the combination therapy.

Conclusions:

• Combining BRAF and MEK inhibitors may offer a more efficacious clinical strategy for BRAF-mutated NSCLC.
• The combination of vemurafenib and trametinib shows potential for managing BRAF-mutated NSCLC by enhancing apoptosis and BIM expression.
• Targeting downstream MEK signaling with trametinib, particularly in combination with a BRAF inhibitor, warrants further clinical investigation for BRAF-mutated NSCLC.